NO981961L - FremgangsmÕte og farmas÷ytisk blanding for regulering av lipidkonsentrasjon - Google Patents
FremgangsmÕte og farmas÷ytisk blanding for regulering av lipidkonsentrasjonInfo
- Publication number
- NO981961L NO981961L NO981961A NO981961A NO981961L NO 981961 L NO981961 L NO 981961L NO 981961 A NO981961 A NO 981961A NO 981961 A NO981961 A NO 981961A NO 981961 L NO981961 L NO 981961L
- Authority
- NO
- Norway
- Prior art keywords
- combination
- methylethyl
- pharmaceutical composition
- concentration control
- lipid concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US615595P | 1995-11-02 | 1995-11-02 | |
PCT/US1996/015854 WO1997016184A1 (en) | 1995-11-02 | 1996-10-02 | Method and pharmaceutical composition for regulating lipid concentration |
Publications (2)
Publication Number | Publication Date |
---|---|
NO981961D0 NO981961D0 (no) | 1998-04-30 |
NO981961L true NO981961L (no) | 1998-05-04 |
Family
ID=21719566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO981961A NO981961L (no) | 1995-11-02 | 1998-04-30 | FremgangsmÕte og farmas÷ytisk blanding for regulering av lipidkonsentrasjon |
Country Status (27)
Country | Link |
---|---|
US (3) | US6124309A (hu) |
EP (1) | EP0858336B1 (hu) |
JP (1) | JPH11515025A (hu) |
KR (2) | KR20040029459A (hu) |
CN (2) | CN1217656C (hu) |
AR (1) | AR004527A1 (hu) |
AT (1) | ATE348607T1 (hu) |
AU (1) | AU720853B2 (hu) |
BG (1) | BG64018B1 (hu) |
BR (1) | BR9611410A (hu) |
CZ (1) | CZ127198A3 (hu) |
DE (1) | DE69636783T2 (hu) |
EA (1) | EA000514B1 (hu) |
ES (1) | ES2279526T3 (hu) |
GE (1) | GEP20001898B (hu) |
HK (1) | HK1016509A1 (hu) |
HU (1) | HUP9901865A3 (hu) |
IL (1) | IL123902A (hu) |
IS (1) | IS4720A (hu) |
NO (1) | NO981961L (hu) |
NZ (2) | NZ512484A (hu) |
PL (1) | PL186714B1 (hu) |
RO (1) | RO120816B1 (hu) |
SK (1) | SK284142B6 (hu) |
UA (1) | UA46069C2 (hu) |
WO (1) | WO1997016184A1 (hu) |
ZA (1) | ZA969187B (hu) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6268392B1 (en) * | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
CN1217656C (zh) * | 1995-11-02 | 2005-09-07 | 沃尼尔·朗伯公司 | 用于调节脂浓度的方法和药物组合物 |
GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
GT199800127A (es) | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
EP1514543A1 (en) * | 1997-08-29 | 2005-03-16 | Pfizer Inc. | Combination therapy comprising atorvastatin and an antihypertensive agent |
EP1063991A1 (en) * | 1998-03-17 | 2001-01-03 | Warner-Lambert Company Llc | Statin-matrix metalloproteinase inhibitor combinations |
US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
HUP0103648A3 (en) * | 1998-09-30 | 2003-10-28 | Warner Lambert Co | Method for preventing or delaying catheter-based revascularization |
CO5140104A1 (es) * | 1999-02-16 | 2002-03-22 | Novartis Ag | Derivados de mevinolina y preparacion farmaceuticas que los contienen |
US20010006656A1 (en) * | 1999-02-17 | 2001-07-05 | University Of Washington | Methods and compositions for inhibiting inflammation associated with pulmonary disease |
AU7717500A (en) * | 1999-09-30 | 2001-04-30 | Merck & Co., Inc. | Anti-hypercholesterolemic drug combination |
EP1092432A1 (fr) * | 1999-10-15 | 2001-04-18 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) | Composes anti-ischemiques |
CN1414848A (zh) * | 1999-11-05 | 2003-04-30 | 沃尼尔·朗伯公司 | Acat抑制剂对斑块破裂的预防 |
BR0113523A (pt) * | 2000-09-01 | 2004-06-29 | Sankyo Co | Composição farmacêutica, kit, e, usos de n-(1-octil-5-carboxi-metil)-4,6-dimetil-indolin-7-il)-2,2-d imetil-propanamida ou um seu sal farmacologicamente aceitável, e de uma composição |
JP2004529069A (ja) | 2000-10-11 | 2004-09-24 | エスペリオン セラピューティクス,インコーポレイテッド | コレステロール管理用のエーテル化合物及び組成物ならびに関連する使用 |
BR0114619A (pt) | 2000-10-11 | 2005-12-13 | Esperion Therapeutics Inc | Composto, composição farmacêutica, métodos para tratar ou prevenir uma doença cardiovascular, uma dislipidemia, uma dislipoproteinemia, um distúrbio do metabolismo da glicose, trombótico e associado com o receptor ativado do proliferador de peroxissoma, a doença de alzheimer, a sìndrome x ou sìndrome metabólica, a septicemia, a obesidade, pancreatite, a hipertensão, doença renal, câncer, a inflamação e a impotência, em um paciente e para reduzir o teor de gordura da carne em animal de criação e de colesterol de ovos de aves domésticas |
US20040122091A1 (en) * | 2000-10-11 | 2004-06-24 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
AU1313602A (en) | 2000-10-11 | 2002-04-22 | Esperion Therapeutics Inc | Ketone compounds and compositions for cholesterol management and related uses |
CN1479721A (zh) | 2000-10-11 | 2004-03-03 | ͨ��ҽ�ƹ�˾ | 用于胆固醇治疗和相关应用的亚砜和双亚砜化合物和组合物 |
US7304093B2 (en) * | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
CA2369967A1 (en) * | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
PE20030324A1 (es) * | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
US20040204502A1 (en) * | 2001-10-11 | 2004-10-14 | Dasseux Jean-Louis Henri | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
US20040192771A1 (en) * | 2001-10-11 | 2004-09-30 | Dasseux Jean-Louis Henri | Ether compounds and compositions for cholesterol management and related uses |
US20050020694A1 (en) * | 2001-10-11 | 2005-01-27 | Dasseux Jean-Louis Henri | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
WO2003077896A1 (en) * | 2002-03-12 | 2003-09-25 | Merck & Co., Inc. | Drug combination therapy |
EP1495034A2 (en) * | 2002-04-10 | 2005-01-12 | Esperion Therapeutics, Inc. | Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses |
JP4187141B2 (ja) * | 2002-04-12 | 2008-11-26 | 興和株式会社 | 新規なトロンボモジュリン発現促進剤 |
PT2404890T (pt) * | 2003-01-23 | 2017-10-23 | Esperion Therapeutics Inc | Compostos de hidroxilo e composições para gestão do colesterol e utilizações relacionadas |
RU2358734C2 (ru) | 2003-08-29 | 2009-06-20 | Кова Ко., Лтд. | Способ стабилизации бляшки с высоким содержанием липидов и способ профилактики ее разрушения |
CA2546079A1 (en) * | 2003-11-17 | 2005-05-26 | Toyo Shinyaku Co., Ltd. | Lipometabolism improver containing pine bark extract |
EP1701931B1 (en) | 2003-12-24 | 2018-10-10 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
AU2005235306B2 (en) * | 2004-04-19 | 2008-08-21 | Loma Linda University | Composition and method of decreasing renal ischemic damage |
TW200605890A (en) * | 2004-07-28 | 2006-02-16 | Sankyo Co | Pharmaceutical compositions for inhibiting arteriosclerosis |
CA2585623C (en) * | 2004-10-27 | 2012-06-05 | Daiichi Sankyo Company Limited | Ortho-substituted benzene derivatives |
TW200619204A (en) * | 2004-12-10 | 2006-06-16 | Kowa Co | Method for reduction, stabilization and prevention of rupture of lipid rich plaque |
AU2006313430B2 (en) * | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
AU2007245410A1 (en) | 2006-04-26 | 2007-11-08 | Rosemont Pharmaceuticals Ltd | Liquid oral compositions |
US20130254787A1 (en) | 2006-05-02 | 2013-09-26 | Invidi Technologies Corporation | Method and apparatus to perform real-time audience estimation and commercial selection suitable for targeted advertising |
US20070269503A1 (en) * | 2006-05-16 | 2007-11-22 | James Walter Burgess | Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof |
US8314080B2 (en) | 2010-04-06 | 2012-11-20 | Kuwait University | Method of treating type I diabetes |
CN103274985B (zh) * | 2010-12-03 | 2016-03-09 | 上海科州药物研发有限公司 | 一种阿托伐他汀氨基酸盐 |
US8586527B2 (en) * | 2011-10-20 | 2013-11-19 | Jaipal Singh | Cerivastatin to treat pulmonary disorders |
DK2771003T3 (en) | 2011-10-28 | 2017-07-17 | Lumena Pharmaceuticals Llc | Bile acid recycling inhibitors for the treatment of pediatric cholestatic liver disease |
CN103304496A (zh) * | 2012-03-08 | 2013-09-18 | 南京工业大学 | 一种合成申嗪霉素方法 |
WO2013171100A1 (en) | 2012-05-16 | 2013-11-21 | Joachim Hans | Polyhydroxylated pentacyclic triterpene acids as hmg-coa reductase inhibitors |
JP6940411B2 (ja) | 2015-03-13 | 2021-09-29 | エスペリオン・セラピューティクス・インコーポレイテッドEsperion Therapeutics, Inc. | Etc1002及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法 |
MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
CN112437765A (zh) | 2019-06-21 | 2021-03-02 | 艾斯柏伦治疗公司 | 贝派地酸的盐形式及其使用方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
CA2003478A1 (en) * | 1988-12-12 | 1990-06-12 | Leonard G. Dennick | Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
CA2048395A1 (en) * | 1990-08-23 | 1992-02-24 | Henry Y. Pan | Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin |
WO1993002048A1 (en) | 1991-07-23 | 1993-02-04 | Schering Corporation | Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof |
AU5538794A (en) * | 1992-10-26 | 1994-05-24 | Merck & Co., Inc. | Biologically active compounds and process therefor |
LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
US5491172A (en) * | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
IL109431A (en) * | 1993-05-14 | 2001-01-11 | Warner Lambert Co | Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds |
AU1095695A (en) * | 1993-11-09 | 1995-05-29 | Brigham And Women's Hospital | Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction |
CN1217656C (zh) * | 1995-11-02 | 2005-09-07 | 沃尼尔·朗伯公司 | 用于调节脂浓度的方法和药物组合物 |
-
1996
- 1996-10-02 CN CN961980109A patent/CN1217656C/zh not_active Expired - Fee Related
- 1996-10-02 SK SK557-98A patent/SK284142B6/sk unknown
- 1996-10-02 UA UA98052811A patent/UA46069C2/uk unknown
- 1996-10-02 JP JP9517342A patent/JPH11515025A/ja not_active Ceased
- 1996-10-02 IL IL12390296A patent/IL123902A/xx not_active IP Right Cessation
- 1996-10-02 HU HU9901865A patent/HUP9901865A3/hu unknown
- 1996-10-02 US US09/051,368 patent/US6124309A/en not_active Expired - Fee Related
- 1996-10-02 GE GEAP19964269A patent/GEP20001898B/en unknown
- 1996-10-02 EP EP96934020A patent/EP0858336B1/en not_active Revoked
- 1996-10-02 KR KR10-2004-7003107A patent/KR20040029459A/ko active Search and Examination
- 1996-10-02 AT AT96934020T patent/ATE348607T1/de not_active IP Right Cessation
- 1996-10-02 NZ NZ512484A patent/NZ512484A/xx unknown
- 1996-10-02 RO RO98-00919A patent/RO120816B1/ro unknown
- 1996-10-02 CN CNA2005100517235A patent/CN1679953A/zh active Pending
- 1996-10-02 ES ES96934020T patent/ES2279526T3/es not_active Expired - Lifetime
- 1996-10-02 NZ NZ319906A patent/NZ319906A/en unknown
- 1996-10-02 PL PL96326365A patent/PL186714B1/pl not_active IP Right Cessation
- 1996-10-02 KR KR10-1998-0703240A patent/KR100449604B1/ko not_active IP Right Cessation
- 1996-10-02 BR BR9611410A patent/BR9611410A/pt not_active Application Discontinuation
- 1996-10-02 EA EA199800420A patent/EA000514B1/ru not_active IP Right Cessation
- 1996-10-02 DE DE69636783T patent/DE69636783T2/de not_active Expired - Fee Related
- 1996-10-02 WO PCT/US1996/015854 patent/WO1997016184A1/en not_active Application Discontinuation
- 1996-10-02 AU AU72539/96A patent/AU720853B2/en not_active Ceased
- 1996-10-02 CZ CZ981271A patent/CZ127198A3/cs unknown
- 1996-10-31 ZA ZA969187A patent/ZA969187B/xx unknown
- 1996-11-01 AR ARP960105005A patent/AR004527A1/es unknown
-
1998
- 1998-04-17 IS IS4720A patent/IS4720A/is unknown
- 1998-04-29 BG BG102417A patent/BG64018B1/bg unknown
- 1998-04-30 NO NO981961A patent/NO981961L/no unknown
-
1999
- 1999-04-21 HK HK99101732A patent/HK1016509A1/xx not_active IP Right Cessation
- 1999-07-01 US US09/345,944 patent/US6093719A/en not_active Expired - Fee Related
- 1999-07-01 US US09/346,503 patent/US6143755A/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO981961L (no) | FremgangsmÕte og farmas÷ytisk blanding for regulering av lipidkonsentrasjon | |
MX9702204A (es) | Tratamiento con ribozimas de enfermedades o condiciones relacionadas con niveles de lipoproteina (a) [lp(a)] en plasma, inhibiendo apolipoproteina (a) [apo(a)]. | |
Ginsberg | Effects of statins on triglyceride metabolism | |
NO20013161L (no) | Preparater av ileum-gallesyretransportinhibitorer og kolesterylesteroverföringsproteininhibitorer for kardiovaskul¶reindikasjoner | |
EE9400341A (et) | Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon | |
NO20100214L (no) | Preparat for a redusere LIPG ekspresjon hos en pasient og anvendelsen av dette | |
DE69628874D1 (de) | Verwendung eines HMG CoA-Reduktase Inhibitors zur Vorbeugung eines zweiten Herzanfalls | |
FI951218A0 (fi) | Menetelmä kokonaiskolesterolin ja matalatiheyksisen lipoproteiinikolestrolin pitoisuuksien pienentämiseksi veressä | |
DE69115909D1 (de) | Verwendung von Phospholipiden zur Herstellung eines topischen Arzneimittels zur Beinflussung des Serumcholesterinspiegels | |
Carson | Tissue factor (coagulation factor III) inhibition by apolipoprotein A-II. | |
Zieve et al. | Post-heparin phospholipase and post-heparin lipase have different tissue origins | |
Bergstrom et al. | Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin | |
DE69429816D1 (de) | C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt | |
Andreassen et al. | Changes in Lp (a) lipoprotein and other plasma proteins during acute myocardial infarction | |
ATE353957T1 (de) | Verwendung von lezithin-cholesterin- azetyltransferase für die behandlung von atherosklerose | |
NO934832L (no) | Farmasöytisk sammensetning for forhindring eller behandling av arterioscherose | |
Cromwell et al. | Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors | |
CA2233558A1 (en) | Method and pharmaceutical composition for regulating lipid concentration | |
Stohler et al. | Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia | |
Pioruńska-Stolzmann et al. | The influence of simvastatin on lipase and cholesterol esterase activity in the serum of men with coronary heart disease | |
Bevilacqua et al. | Effects of fluvastatin on lipids profiles and t-PA mass concentration in coronary patients with primary hypercholesterolemia and high LP (a) | |
Hadjiisky et al. | Effect of pravastatin, a HMG CoA reductase inhibitor, on blood lipids and aortic lipidosis in cholesterol-fed White Carneau pigeons | |
Suckling | Anti-atherosclerotics-Bile acid sequestrants, cholesterol absorption and fibrates | |
La Belle et al. | Quality of life in a 6-week study of simvastatin vs pravastatin | |
Kleinfeld | The role of free fatty acids in CTL-target cell interactions |